Attached files
| file | filename |
|---|---|
| EX-99.02 - EXHIBIT 99.02 - Inspyr Therapeutics, Inc. | v408639_ex99-02.htm |
| EX-99.01 - EXHIBIT 99.01 - Inspyr Therapeutics, Inc. | v408639_ex99-01.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 29, 2015 (April 28, 2015)
GENSPERA, INC.
(Exact name of registrant as specified in Charter)
| Delaware | 0001421204 | 20-0438951 | ||
|
(State or other jurisdiction of incorporation or organization) |
(Commission File No.) | (IRS Employee Identification No.) |
2511 N Loop 1604 W, Suite 204
San Antonio, TX 78258
(Address of Principal Executive Offices)
210-479-8112
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
Commencing on April 28, 2015 and continuing throughout the week, representatives of GenSpera, Inc. (the “Company”) will be presenting to select accredited and institutional investors in connection with a non-deal road show. Filed herewith as Exhibit 99.01 are the slides that are being presented.
The information contained in this Item 7.01 to this Current Report on Form 8-K and the exhibit attached hereto pertaining to this item shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in the exhibits to this Form 8-K relating to this item 7.01 shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 8.01 Other Events.
On April 28, 2015, the Company announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,957,016. The patent expands the Company’s intellectual property portfolio by claiming numerous compositions for the Company’s prodrugs designed to be activated by Prostate Specific Antigen (PSA). A copy of the press release is attached to this report as Exhibit 99.02.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No. |
Description |
|||
| 99.01 | Slides to be presented during non-deal roadshow | |||
| 99.02 | Press release dated April 28, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 29, 2015
| GenSpera, Inc. | ||
| By: |
/s/ Craig Dionne | |
|
Craig Dionne Chief Executive Officer | ||
INDEX OF EXHIBITS
|
Exhibit No. |
Description |
|||
| 99.01 | Slides to be presented during non-deal roadshow | |||
| 99.02 | Press release dated April 28, 2015 |